Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04690829 · ClinicalTrials.gov registry record

Biomarkers in Ocular Inflammation and Uveitis

A clinical trial, sponsored by National Eye Institute (NEI).

Completed
Registry status
69
Enrollment target

NCT04690829 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 69 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04690829 has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
69 participants
Enrollment target

Study Summary

Background: Uveitis refers to a large group of inflammatory diseases in the eye. The inflammation can be caused by many factors, such as trauma, medicine, or infection. It can also be caused by systemic diseases. Uveitis and ocular inflammation can cause vision loss. Both children and adults can have uveitis. Standard treatment is to suppress the immune system. But this can result in high costs as well as bad side effects. Researchers want to look at data from NEI studies. They want to learn more about how uveitis progresses and responds to treatment. Objective: To find biomarkers to better understand uveitic diseases, assess disease severity, and create outcome measures of response to treatment and disease activity. Eligibility: People ages 4 and older from certain NEI studies who have uveitis or ocular inflammation, and healthy volunteers Design: Data will be taken from NEI studies from January 1, 2000, to December 31, 2025. Data will only be collected for participants who agreed to let their data be used for future research. No new tests will be done on any samples. Laboratory results and images will be used. Medical chart data, such as symptoms, medicine history, and treatment course, will be used. Personal data, such as name, medical record number, and date of birth, will be used. COVID-19 has been reported to cause eye changes. Exam findings of participants who had COVID-19 will be reviewed as well. Machine learning will be used to study the data. This study will take place at the NIH Clinical Center. All data will be securely stored.

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2020-12-29
Est. Completion 2022-11-16

Sponsor

National Eye Institute (NEI)

221 total trials

What the Registry Record Tells You About NCT04690829

The ClinicalTrials.gov registry entry for NCT04690829 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT04690829 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04690829 about?

NCT04690829 is a clinical study titled "Biomarkers in Ocular Inflammation and Uveitis". Background: Uveitis refers to a large group of inflammatory diseases in the eye. The inflammation can be caused by many factors, such as trauma, medicine, or infection. It can also be caused by systemic diseases. Uveitis and ocular inflammation can cause vision loss. Both children and adults can ha...

What is the current status of trial NCT04690829?

This trial is currently completed. The enrollment target is 69 participants. The study started on 2020-12-29. Estimated completion is 2022-11-16.

Who is sponsoring clinical trial NCT04690829?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.